stoxline Quote Chart Rank Option Currency Glossary
  
180 Life Sciences Corp. (ATNF)
1.18  0.01 (0.85%)    05-16 16:00
Open: 1.17
High: 1.265
Volume: 127,385
  
Pre. Close: 1.17
Low: 1.1
Market Cap: 7(M)
Technical analysis
2025-05-16 4:38:05 PM
Short term     
Mid term     
Targets 6-month :  1.71 1-year :  2
Resists First :  1.47 Second :  1.71
Pivot price 1.09
Supports First :  1 Second :  0.72
MAs MA(5) :  1.14 MA(20) :  1.03
MA(100) :  1.26 MA(250) :  1.8
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  50.7 D(3) :  48.5
RSI RSI(14): 59
52-week High :  17.75 Low :  0.65
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ATNF ] has closed below upper band by 32.2%. Bollinger Bands are 7.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.27 - 1.27 1.27 - 1.28
Low: 1.09 - 1.09 1.09 - 1.1
Close: 1.17 - 1.18 1.18 - 1.19
Company Description

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Headline News

Thu, 01 May 2025
180 Life Sciences nears patent for post-surgery cognitive aid - Investing.com

Thu, 01 May 2025
Patent Breakthrough: 180 Life Sciences Develops First Treatment to Prevent Post-Surgery Cognitive Decline in Elderly - Stock Titan

Wed, 30 Apr 2025
180 Life Sciences Corp. Announces Share Repurchase - ACCESS Newswire

Wed, 30 Apr 2025
180 Life Sciences Corp. Announces Share Repurchase | ATNF Stock News - GuruFocus

Wed, 30 Apr 2025
180 Life Sciences Launches Massive 23% Share Reduction Plan: Key Details of $1M Strategic Buyback - Stock Titan

Sun, 27 Apr 2025
Press Release Distribution & PR Platform - ACCESS Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 6 (M)
Shares Float 3 (M)
Held by Insiders 48.9 (%)
Held by Institutions 31 (%)
Shares Short 89 (K)
Shares Short P.Month 57 (K)
Stock Financials
EPS -15.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.91
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -43.9 %
Return on Equity (ttm) -135.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.11
Qtrly Earnings Growth 0 %
Operating Cash Flow -1 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.08
PEG Ratio 0
Price to Book value 0.4
Price to Sales 0
Price to Cash Flow -4.55
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android